scispace - formally typeset
M

Manuel Monreal

Researcher at Autonomous University of Barcelona

Publications -  499
Citations -  23299

Manuel Monreal is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Pulmonary embolism & Medicine. The author has an hindex of 66, co-authored 437 publications receiving 18821 citations. Previous affiliations of Manuel Monreal include Carlos III Health Institute & Universidad Católica San Antonio de Murcia.

Papers
More filters
Journal ArticleDOI

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Behnood Bikdeli, +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI

Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.

TL;DR: The simplified PESI has similar prognostic accuracy and clinical utility and greater ease of use compared with the original PESi and is applicable to outpatients with acute pulmonary embolism.
Journal ArticleDOI

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

JW tenCate, +113 more
TL;DR: Fixed-dose, subcutaneous low-molecular-weight heparin is as effective and safe as adjusted- dose, intravenous unfractionated Heparin for the initial management of venous thromboembolism, regardless of whether the patient has pulmonary embolism or a history of venOUS thrombolism.
Journal ArticleDOI

Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.

TL;DR: The clinical predictors identified in the present study should be included in any clinical risk stratification scheme to optimally adapt the treatment of PE to the risk of the fatal outcome.